Trinity Biotech plc (TRIB)
Market Cap | 12.31M |
Revenue (ttm) | 59.13M |
Net Income (ttm) | -20.33M |
Shares Out | 9.47M |
EPS (ttm) | -2.15 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 44,771 |
Open | 1.270 |
Previous Close | 1.290 |
Day's Range | 1.270 - 1.400 |
52-Week Range | 1.050 - 3.550 |
Beta | 1.13 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 15, 2024 |
About TRIB
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and o... [Read more]
Financial Performance
In 2023, Trinity Biotech's revenue was $56.83 million, a decrease of -9.10% compared to the previous year's $62.52 million. Losses were -$24.02 million, -41.43% less than in 2022.
Financial StatementsNews
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript
Trinity Biotech Plc (NASDAQ:TRIB) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Office...
Trinity Biotech Announces Q3 2024 Financial Results
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to a...
Trinity Biotech to Announce Q3 2024 Financial Results
Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, inc...
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology
DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women-
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearab...
Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology
DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, includi...
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, includ...
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
DUBLIN, Ireland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, includin...
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech plc (TRIB) Q2 2024 Earnings Call Transcript
Trinity Biotech plc (NASDAQ:TRIB) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Simon Dunne ...
Trinity Biotech Announces Q2 2024 Financial Results
-Q2, 2024 total revenues of $15.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business-
Trinity Biotech to Announce Q2 2024 Financial Results
Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements
DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl...
Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience
-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth-
Trinity Biotech Announces Appointment of A New CFO
DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable...
Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable...
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, i...
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable...
Trinity Biotech plc (TRIB) Q1 2024 Earnings Call Transcript
Trinity Biotech plc (NASDAQ:TRIB) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald -...
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO 1 on annualized revenues of approximately $75 million by Q2 2025-
Trinity Biotech plc to Announce Q1 2024 Financial Results
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagno...